Drugs / Acadesine
Acadesine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01813838 | Jun 2013 | — | Groupe Francophone des Myelodysplasies | Terminated | No outcome recorded |
| Phase 1/2 | NCT00559624 | Dec 2007 → Dec 2010 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Advancell - Advanced In Vitro Cell Technologies, S.A. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00872001 Comparator | Apr 2009 → Oct 2010 | left ventricular failure, myocardial infarction, stroke disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acadesine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00559624 ↗ |
| Known as | Acadesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1551724 ↗ |
| Known as | GP-1-110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1551724 ↗ |
| Known as | NSC-105823 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1551724 ↗ |
| Modality | Small molecule | — CHEMBL1551724 ↗ |
| Route | Intravenous | “4 hour intravenous infusion” NCT00559624 ↗ |